Skip to main content
. Author manuscript; available in PMC: 2010 Aug 9.
Published in final edited form as: JPEN J Parenter Enteral Nutr. 2009 Apr 14;33(4):368–374. doi: 10.1177/0148607108327392

Figure 2.

Figure 2

Patient flow diagram. Patients are randomized in a blind fashion within 48 hours and receive 1 of 2 treatments within 72 hours; either (a) enteral glutamine, zinc, and selenium plus intravenous metoclopramide or (b) enteral Beneprotein™ powder (a whey protein supplement; Nestle Nutrition, Vevey, Switzerland) plus intravenous normal saline. Treatment is continued for whichever occurs first, discharge from the pediatric intensive care unit, loss of enteral tubes and intravenous access, or 28 days.